Mangoceuticals (NASDAQ:MGRX) Raised to Sell at Wall Street Zen

Mangoceuticals (NASDAQ:MGRX) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mangoceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Mangoceuticals Stock Up 3.2%

NASDAQ MGRX opened at $0.42 on Friday. The stock’s 50-day moving average price is $0.40 and its 200-day moving average price is $0.93. Mangoceuticals has a 52 week low of $0.16 and a 52 week high of $2.75. The company has a market capitalization of $7.08 million, a P/E ratio of -0.16 and a beta of 2.54.

Mangoceuticals (NASDAQ:MGRX) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.13 EPS for the quarter. Mangoceuticals had a negative return on equity of 109.38% and a negative net margin of 4,536.70%.The firm had revenue of $0.09 million for the quarter.

Institutional Trading of Mangoceuticals

Several institutional investors have recently made changes to their positions in the business. Armistice Capital LLC purchased a new stake in shares of Mangoceuticals during the fourth quarter worth about $1,137,000. Ikarian Capital LLC purchased a new stake in shares of Mangoceuticals during the fourth quarter worth about $102,000. Jane Street Group LLC purchased a new stake in shares of Mangoceuticals during the fourth quarter worth about $35,000. Boothbay Fund Management LLC purchased a new position in Mangoceuticals during the 4th quarter valued at approximately $28,000. Finally, Virtu Financial LLC purchased a new position in Mangoceuticals during the 4th quarter valued at approximately $25,000. Hedge funds and other institutional investors own 56.72% of the company’s stock.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.